[Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy].
Interferon-beta (IFN-beta) therapy can trigger immune adverse effects. We report a patient, who was treated for multiple sclerosis (MS) by IFN-beta during 3 years before developing a severe colitis due to Crohn's disease (CD). Neurological manifestations may occur in CD but rarely mimic MS. This report's points highlight the possible association of MS and CD, where IFN-beta therapy probably unmasked CD. Indeed, similar cases of CD flares have been reported after IFN-alpha therapy for chronic C hepatitis.
Samson
M
M
Service de médecine interne et maladies systémiques, CHU de Dijon, hôpital Général, 3, rue du Faubourg-Raines, 21000 Dijon, France. samsonmaxime@gmail.com
Audia
S
S
Duchêne
C
C
Perinet
I
I
Bielefeld
P
P
Besancenot
J-F
JF
D003424:Crohn Disease / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D007155:Immunologic Factors; D016899:Interferon-beta